Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04000009 · ClinicalTrials.gov registry record · Phase 3
Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment
A Phase 3 study, sponsored by ACADIA Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 235
- Enrollment target
NCT04000009 is a Phase 3 study that was terminated before completion, run by ACADIA Pharmaceuticals. The registered enrollment target is 235 participants.
The verdict
NCT04000009, a Phase 3 study, was terminated before completion, sponsored by ACADIA Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 235 participants
- Enrollment target
Study Summary
To assess the safety and tolerability of long-term pimavanserin treatment in subjects with major depressive disorder and inadequate response to antidepressant treatment.
Interventions
- DRUG Pimavanserin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 235 participants |
| Start Date | 2019-06-06 |
| Est. Completion | 2021-02-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04000009
The ClinicalTrials.gov registry entry for NCT04000009 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 235 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ACADIA Pharmaceuticals, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pimavanserin is the first listed.
NCT04000009 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04000009 about?
NCT04000009 is a clinical study titled "Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment". To assess the safety and tolerability of long-term pimavanserin treatment in subjects with major depressive disorder and inadequate response to antidepressant treatment.
What is the current status of trial NCT04000009?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 235 participants. The study started on 2019-06-06. Estimated completion is 2021-02-22.
What interventions are being tested in trial NCT04000009?
The interventions under investigation include: Pimavanserin (DRUG).
Who is sponsoring clinical trial NCT04000009?
This trial is sponsored by ACADIA Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.